BUFFALO GROVE, Ill.--(BUSINESS WIRE)--RestorGenex Corporation (OTCQB: RESX), a specialty biopharmaceutical company initially focused on developing products for dermatology, ophthalmology and women’s health, today announced that Chief Scientific Officer David Sherris, Ph.D., will present scientific data on the Company’s proprietary RES-529 program in ophthalmology. Dr. Sherris’s presentation at the Cambridge Healthtech Institute conference is scheduled for Monday, October 6, 2014 at 4:55 pm (EDT) at the Westin Boston Waterfront Hotel.
Help employers find you! Check out all the jobs and post your resume.
Help employers find you! Check out all the jobs and post your resume.
